Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Quantum Biopharma Ltd (QNTM)

Quantum Biopharma Ltd (QNTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 GlobeNewswire - Thu May 7, 6:00AM CDT

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum ” or the “ Company ”), has reported its financial and operational results for...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum BioPharma Provides Corporate Update GlobeNewswire - Mon Apr 27, 6:45PM CDT

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April 27, 2026...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant GlobeNewswire - Wed Apr 22, 8:16AM CDT

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ”), a biopharmaceutical company dedicated to building a portfolio of...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied GlobeNewswire - Thu Apr 2, 7:30AM CDT

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis GlobeNewswire - Wed Apr 1, 7:02AM CDT

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis GlobeNewswire - Mon Mar 30, 6:50AM CDT

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum Biopharma Provides Corporate Update GlobeNewswire - Fri Mar 27, 6:30PM CDT

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 27, 2026...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status GlobeNewswire - Fri Mar 27, 7:10AM CDT

Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd ™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis GlobeNewswire - Thu Mar 26, 7:00AM CDT

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd GlobeNewswire - Mon Mar 23, 7:24AM CDT

TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), "Company"), a biopharmaceutical company dedicated...

QNTM : 4.88 (-2.59%)
QNTM.CN : 6.7000 (-3.74%)

Barchart Exclusives

Palantir Stock Has a ‘High-Class Problem’: Demand for Its Software Is Far Outpacing Supply Barchart - Sun May 10, 4:00PM CDT
Palantir’s greatest challenge may no longer be demand, but how quickly it can deliver AI software to customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.